Financials

  • Market Capitalization 2.36 B
  • Employee 357
  • Founded 2009
  • CEO N/A
  • Website www.nurixtx.com
  • Headquarter Delaware, United States
  • FIGI BBG00SDJ8M78
  • Industry Biotecnología
Ingresos totales
Beneficio neto
Beneficio básico por acción
Deuda total
Flujo de caja libre
Efectivo y equivalentes
Ratio precio/beneficio
-5.54
Relación precio/flujo de caja
17.45

Related tickers

#NombrePrecio24h %7d %1M %1A %CapitalizaciónÚltimos 7 días
1865
VCEL
Vericel Corporation - Common Stock
47.49 USD+1.04%+0.87%+25.40%+30.65%2.43 B USD
1872
AGIO
Agios Pharmaceuticals, Inc. - Common Stock
40.55 USD-1.65%+2.35%+36.58%-6.55%2.41 B USD
1887
SLS
SELLAS Life Sciences Group, Inc. - Common Stock
12.62 USD-1.10%-9.21%+59.75%+540.61%2.35 B USD
1888
TRVI
Trevi Therapeutics, Inc. - Common Stock
16.52 USD-7.40%-8.63%+14.64%+134.99%2.35 B USD

Noticias